Sprimeo Articles
Novartis gains positive CHMP opinion for Rasilamlo, as do CSL Behring for Hizentra and Provepharm for Proveblue
21 February 2011
Showing 1-1 of 1 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
